Drug intelligence / Profile preview

NPD-1911

Development stage
Unknown
Lead developer
Nogra Pharma Ltd.
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

NPD-1911 is an investigational oligonucleotide therapeutic being developed by Nogra Pharma for the treatment of immune-inflammatory-mediated diseases, including Crohn's disease. It is part of Nogra Pharma's proprietary oligonucleotide platform, which focuses on designing synthetic oligonucleotides capable of down-regulating the expression of specific target proteins involved in inflammatory pathways. While the exact molecular target and mechanism of action have not been publicly disclosed, the drug is currently in Phase I clinical development, following the company's strategy of targeting immune-mediated conditions with RNA-based therapies.

Beyond the preview

Go deeper on NPD-1911.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPD-1911.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call